Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference
Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference
Aileron Therapeutics, Inc. is a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Aileron's lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Currently, LTI-03 is being evaluated in a Phase AUSTIN, Texas, July 30, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that Brian Windsor, Ph.D., President and Chief Executive Officer, will present at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13, 2024 at 4:00 p.m. EDT in Boston, MA.
醫療公司Aileron Therapeutics，Inc.（"艾勒隆"）（納斯達克：ALRN）致力於推進一系列突破性首創藥物的開發，以滿足孤兒肺部和纖維化疾病領域的重大未滿足醫療需求。2024年8月13日星期二下午4點，在馬薩諸塞州波士頓，總裁兼首席執行官Brian Windsor博士將在Canaccord Genuity第44屆年度成長會議上發表演講。
A live webcast of the event can be accessed at . A replay of the webcast will be available for 90 days following the presentation.
現場網絡直播可以訪問。演講後90天內，網絡直播的重播將可用。
About Aileron Therapeutics
關於Aileron Therapeutics
Aileron Therapeutics, Inc. is a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Aileron's lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Currently, LTI-03 is being evaluated in a Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis. Aileron's second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the US and EU and Fast Track Designation in the US.
全球貨幣 (ALRN) 製藥公司Aileron Therapeutics正在推進首批用於治療孤兒肺部疾病和纖維化的一流藥物，這是一種全新的合成肽，具有針對肺泡上皮細胞生存和受限制的纖維信號的雙重機制。目前，該藥物正在接受I期臨床試驗，用於治療特發性肺纖維化。Aileron的第二款產品候選藥LTI-01是一種酶前體，已完成了用於治療侷限性胸膜滲出液的I期b和IIa臨床試驗。LTI-01已在美國和歐盟獲得孤兒藥物認證，並在美國獲得了快速通道認證。
Investor Relations & Media Contact:
Argot Partners
[email protected]
212-600-1902
投資者關係和媒體聯繫人：
阿哥特合夥人。
[email protected]
212-600-1902
SOURCE Aileron Therapeutics, Inc.
Aileron Therapeutics, Inc的消息來源。
譯文內容由第三人軟體翻譯。
